American Century Companies’s Sarepta Therapeutics SRPT Stock Holding History

American Century Companies’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.05M	Buy	+94,400	New	+$1.83M	﹤0.01%	2108
2024 Q4	–	Sell	-6,883	Closed	-$860K	–	2950
2024 Q3	$860K	Sell	6,883 -301	-4%	-$41.6K	﹤0.01%	2289
2024 Q2	$1.14M	Buy	7,184 +889	+14%	+$114K	﹤0.01%	2132
2024 Q1	$815K	Sell	6,295 -1,835	-23%	-$225K	﹤0.01%	2234
2023 Q4	$784K	Sell	8,130 -584,203	-99%	-$56M	﹤0.01%	2178
2023 Q3	$71.8M	Sell	592,333 -1,021	-0.2%	-$115K	0.06%	351
2023 Q2	$68M	Sell	593,354 -359,850	-38%	-$46.4M	0.05%	358
2023 Q1	$131M	Buy	953,204 +270,542	+40%	+$35.1M	0.1%	235
2022 Q4	$88.5M	Sell	682,662 -284,035	-29%	-$32.9M	0.07%	294
2022 Q3	$107M	Sell	966,697 -217,752	-18%	-$21.9M	0.09%	244
2022 Q2	$88.8M	Buy	1,184,449 +365,376	+45%	+$26.9M	0.07%	287
2022 Q1	$64M	Buy	+819,073	New	+$62.7M	0.04%	390
2021 Q1	–	Sell	-2,419	Closed	-$412K	–	2251
2020 Q4	$412K	Buy	2,419 +12	+0.5%	+$1.78K	﹤0.01%	1626
2020 Q3	$338K	Buy	2,407 +20	+0.8%	+$3.04K	﹤0.01%	1501
2020 Q2	$383K	Buy	+2,387	New	+$325K	﹤0.01%	1373
2019 Q3	–	Sell	-407,524	Closed	-$61.9M	–	1307
2019 Q2	$61.9M	Buy	407,524 +29,117	+8%	+$3.54M	0.06%	325
2019 Q1	$45.1M	Sell	378,407 -47,173	-11%	-$6.06M	0.05%	374
2018 Q4	$46.4M	Buy	425,580 +18,760	+5%	+$2.35M	0.05%	348
2018 Q3	$65.7M	Buy	+406,820	New	+$55.6M	0.06%	314
2018 Q2	–	Sell	-63,009	Closed	-$4.67M	–	1354
2018 Q1	$4.67M	Buy	63,009 +5,951	+10%	+$397K	﹤0.01%	850
2017 Q4	$3.17M	Sell	57,058 -15,336	-21%	-$812K	﹤0.01%	926
2017 Q3	$3.28M	Buy	72,394 +17,100	+31%	+$683K	﹤0.01%	944
2017 Q2	$1.86M	Buy	55,294 +17,877	+48%	+$582K	﹤0.01%	1048
2017 Q1	$1.11M	Sell	37,417 -235	-0.6%	-$7.27K	﹤0.01%	1124
2016 Q4	$1.03M	Buy	37,652 +54	+0.1%	+$2.17K	﹤0.01%	1125
2016 Q3	$2.31M	Buy	37,598 +3,442	+10%	+$104K	﹤0.01%	1038
2016 Q2	$651K	Buy	+34,156	New	+$633K	﹤0.01%	1209
2016 Q1	–	Sell	-29,987	Closed	-$1.16M	–	1369
2015 Q4	$1.16M	Sell	29,987 -20,321	-40%	-$659K	﹤0.01%	1098
2015 Q3	$1.61M	Buy	50,308 +18,485	+58%	+$627K	﹤0.01%	1044
2015 Q2	$968K	Sell	31,823 -3,364	-10%	-$68.8K	﹤0.01%	1150
2015 Q1	$467K	Sell	35,187 -152	-0.4%	-$2.03K	﹤0.01%	1251
2014 Q4	$511K	Buy	35,339 +1,966	+6%	+$33.3K	﹤0.01%	1282
2014 Q3	$704K	Buy	33,373 +191	+0.6%	+$4.31K	﹤0.01%	1243
2014 Q2	$988K	Buy	+33,182	New	+$1.05M	﹤0.01%	1220
2013 Q4	–	Sell	-28,010	Closed	-$1.32M	–	1495
2013 Q3	$1.32M	Buy	28,010 +1,730	+7%	+$66.6K	﹤0.01%	1170
2013 Q2	$1M	Buy	+26,280	New	+$940K	﹤0.01%	1201

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies's SRPT Position: Q1 2026 in Review

American Century Companies opened a new position in Sarepta Therapeutics (SRPT) in Q1 2026: 94,400 shares worth $2.05M. The stake represents ﹤0.01% of the portfolio and ranks #2108 among its holdings. This is a return to the name: American Century Companies previously reported a position in SRPT as recently as Q3 2024.

American Century Companies first reported a position in SRPT in Q2 2013 and has held it in 36 quarters since. The position peaked at $131M in Q1 2023. 340 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

American Century Companies held 94,400 shares of Sarepta Therapeutics worth $2.05M as of Q1 2026.
Sarepta Therapeutics was a new American Century Companies position in Q1 2026.
Sarepta Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q1 2026, its #2108 holding.
American Century Companies first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 36 quarters since.
American Century Companies's Sarepta Therapeutics position peaked at $131M in Q1 2023.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.